Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration

doi:10.16352/j.issn.1001-6325.2023.07.1090

Abstract

Abstract: Objective To investigate the expression and clinical significance of silent information regulator 2 (SIRT2) form tissue of urothelial bladder cancer(UBC) and the effects of down-regulation of SIRT2 on the proliferation, invasion and migration of bladder cancer cells. Methods The expression of SIRT2 protein was detected in 95 samples of urothelial bladder cancer tissues and 39 paracancerous tissues using the immunohistochemical EnVision method. Its relationship with clinicopathological parameters was analyzed. The expression of SIRT2 mRNA in bladder cancer cell lines was detected by RT-qPCR, and the expression levels of SIRT2 protein in bladder cancer cell lines, 12 pairs of fresh bladder cancer tissues were detected by Western blot. Lentiviral infection was used to stably downregulate the SIRT2 gene in bladder cancer cell line T24. CCK8 and cell colony assays were performed to detect changes in cell proliferation ability and Transwell assay to detect changes in cell invasion and migration activity. Results The positive expression rate of SIRT2 in urothelial bladder cancer tissues was 84%(80/95), which was higher than that in normal uroepithelial tissues (5%, 2/39) (P<0.05). The expression rate of SIRT2 was higher in the high-grade uroepithelial cancer group (95%, 38/40) than in the low-grade group (76%, 42/55) (P<0.05); The expression rate was higher in the muscle-infiltrated group (96%, 24/25) than in the non-muscle-infiltrated group (80%, 56/70) (P<0.05). Expression of SIRT2 protein was higher in fresh bladder cancer tissues than in normal tissues adjacent to the cancer. Expression of mRNA and protein of SIRT2 were also upregulated in bladder cancer cell lines. Knockdown of SIRT2 in T24 cells resulted in a significant decrease in cell activity of proliferation, invasion and migration (P<0.05). Conclusions SIRT2 is highly expressed in bladder uroepithelial carcinoma, and interfers with SIRT2 significantly and so inhibites bladder cancer cell proliferation, invasion and migration.

Key words: SIRT2, urothelial bladder cancer, immunohistochemistry, proliferation, invasion and migration

CLC Number:

R737.1

JIN Xiaoxia, LU Xiaoyun, LIU Yushan, LIANG Lina. Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration[J]. Basic & Clinical Medicine, 2023, 43(7): 1090-1096.

References 12

[1]	Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review[J]. JAMA, 2020, 324:1980-1991.
[2]	曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13:63-69.
[3]	白冰, 张海芳, 杨庆良, 等. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42:940-944.
[4]	W?troba M, Dudek I, Skoda M, et al. Sirtuins, epigenetics and longevity[J]. Ageing Res Rev, 2017, 40:11-19.
[5]	Wang Y, Yang J, Hong T, et al. SIRT2: controversy and multiple roles in disease and physiology[J]. Ageing Res Rev, 2019, 55:100961. doi: 10.1016/j.arr.2019.100961.
[6]	Liu HY, Liu YY, Yang F, et al. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer[J]. Nucleic Acids Res, 2020, 48:3638-3656.
[7]	Li C, Zhou Y, Kim JT, et al. Regulation of SIRT2 by Wnt/beta-catenin signaling pathway in colorectal cancer cells[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868:118966. doi: 10.1016/j.bbamcr.2021.118966.
[8]	Zhu H, Hu Y, Zeng C, et al. The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in non-small cell lung cancer[J]. Theranostics, 2020, 10:2188-2200.
[9]	Aventaggiato M, Vernucci E, Barreca F, et al. Sirtuins’ control of autophagy and mitophagy in cancer[J]. Pharmacol Ther, 2021, 221:107748. doi: 10.1016/j.pharmthera.2020.107748.
[10]	Jin X, Wei Y, Xu F, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity[J]. J Cancer, 2018, 9:2012-2023.
[11]	Liu CW, Lin YC, Hung CM, et al. CHM-1, a novel microtubule-destabilizing agent exhibits antitumor activity via inducing the expression of SIRT2 in human breast cancer cells[J]. Chem Biol Interact, 2018, 289:98-108.
[12]	Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity[J]. Cancer Cell, 2011, 20:487-499.

[1]	XIAO Yanhong, JIANG Mingdong, LIN Yeyuan, RAN Can, LIANG Bo. Scutellarin inhibits proliferation and migration of human prostate cancer cell line PC-3 [J]. Basic & Clinical Medicine, 2024, 44(9): 1229-1235.
[2]	YAO Anjun, CHEN Lingzi, JIN Huixian. Docosahexaenoic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2024, 44(8): 1107-1112.
[3]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[4]	CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue. Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926 [J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
[5]	ZHANG Pengju, LI Jie, ZHANG Mengdi, SUN Shaoke, XU Yinzhe. KAT8 promotes the proliferation of colorectal cancer cell lines by enhancing METTL3 expression [J]. Basic & Clinical Medicine, 2024, 44(7): 931-939.
[6]	GAO Yinjie, TONG Anli. Mechanisms of cell death and proliferation of aldosterone-producing adenoma [J]. Basic & Clinical Medicine, 2024, 44(6): 758-762.
[7]	WANG Tingting, XIAO Ning, LIN Dianxin, DONG Haitao. Allicin inhibits the proliferation of oral cancer cells line CAL27 [J]. Basic & Clinical Medicine, 2024, 44(5): 673-676.
[8]	JIA Anna, GUO Jinxin, ZHANG Xuan, ZHAN Shijia, YU Yongbo, GUO Yongli, CHANG Yan. Regulation of TMEFF1 on proliferation of neuroblastoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(5): 637-644.
[9]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[10]	LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453.
[11]	GUO Hongjiang, XU Yeting, ZHANG Diya, QIU Jiaxing, WANG Yucheng, JU Rui, GUO Lei. Effect of carboxyamidotriazole-orotate on proliferation and fatty acid anabolism of human pancreatic cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 440-446.
[12]	LI Na, LI Tao, YANG Dongli, YAO Yuan. Honokiol inhibits the proliferation of human adipose-derived mesenchymal stem cells [J]. Basic & Clinical Medicine, 2024, 44(4): 483-488.
[13]	ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin. Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib [J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
[14]	AN Qi, QI Guangzhao, HAN Chao. Aucubin inhibits the proliferation of human hepatocellular carcinoma cells line HepG2 [J]. Basic & Clinical Medicine, 2024, 44(3): 333-338.
[15]	JIA Anna, ZHAN Shijia, ZHANG Xuan, GUO Jinxin, YU Yongbo, GUO Yongli, CHANG Yan. Regulatory effect of C12ORF66 on viability of MYCN amplified high-risk neuroblastoma cells [J]. Basic & Clinical Medicine, 2024, 44(3): 288-294.